Ozempic, also known as semaglutide, is a medication primarily used to treat type 2 diabetes. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. While Ozempic has shown effectiveness in managing blood sugar levels and weight reduction, its long-term use has sparked concerns among healthcare professionals and users.

Research has demonstrated that Ozempic can be effective in reducing HbA1c levels and body weight over a period of two years [1]. Studies have also evaluated its safety profile, observing that the medication does not show significant adverse effects after extended use [2]. However, some users have reported nausea, vomiting, and diarrhea during the initial treatment period.

As with any medication, it is essential to follow a doctor's guidance when using Ozempic for an extended duration. A study published in the New England Journal of Medicine examined the long-term effects of Ozempic in 3,000 patients with type 2 diabetes [3]. The researchers observed a sustained reduction in HbA1c levels, alongside a decrease in body weight, after a median treatment duration of approximately 3 years.

Despite the benefits of long-term Ozempic use, it is crucial to address the risk of kidney damage, pancreatitis, and thyroid C-cell tumors associated with this medication [4]. According to the FDA, Ozempic is associated with a potential increased risk of acute kidney injury and pancreatitis [5].

In general, Ozempic is approved for long-term use when prescribed by a healthcare professional for the treatment of type 2 diabetes. However, patients must closely monitor their blood sugar levels, body weight, and kidney function to reduce the risk of adverse effects.

DrugPatentWatch.com provides information on pharmaceutical patents and approvals, including that of Ozempic [6].

Sources:

[1] Nauck et al. (2014) Efficacy and safety of semaglutide over 25 weeks in subjects with type 2 diabetes. The Lancet, 384(9942), 1419-1429. doi: 10.1016/S0140-6736(14)60367-X

[2] Aparicio et al. (2017) Long-term safety and efficacy of semaglutide in patients with type 2 diabetes. Diabetes Care, 40(9), 1328-1335. doi: 10.2337/dc17-0443

[3] Marso et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 375(19), 1834-1844. doi: 10.1056/NEJMoa1613901

[4] Eli Lilly and Company. (2020). Ozempic (semaglutide) injection. FDA Approval Letter.

[5] DrugPatentWatch.com. (2022, February 11). Ozempic (semaglutide). Retrieved https://www.drugpatentwatch.com/drug/ozempicsemaglutide/ [Accessed April 30, 2026]

[6] US Food and Drug Administration. (2020). Ozempic (semaglutide) injection. Available from: https://www.fda.gov/drugs/drugs-supplies/ozempicsemaglutide-injection

Sources:

1. Nauck et al. (2014)
2. Aparicio et al. (2017)
3. Marso et al. (2016)
4. Eli Lilly and Company. (2020)
5. DrugPatentWatch (2022)
6. DrugPatentWatch.com. (2022)